Recursion Pharmaceuticals, Inc. (RXRX) vs TransMedics Group, Inc. (TMDX)
A side-by-side comparison of Recursion Pharmaceuticals, Inc. and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
RXRX
Recursion Pharmaceuticals, Inc.
$4.08HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
TMDX
TransMedics Group, Inc.
$79.23HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
Total return — RXRX vs TMDX
growth of $100 · dividends reinvested · last 5yRXRX -77.4% (-25.7%/yr)TMDX +185.0% (+23.3%/yr)TMDX compounded faster over this window
Log scale — wide-divergence pair
RXRX TMDX
RXRX vs TMDX: by the numbers
- •TMDX is the larger company ($2.74B vs $2.14B market cap).
- •TMDX is profitable (22.69% net margin) while RXRX runs a net loss (-945.92%).
- •TMDX grew revenue faster over the past five years (86.12% vs 45.50% CAGR).
Metrics side by side
Valuation
| Metric | RXRX | TMDX |
|---|---|---|
| P/E ratio | N/A | 20.52 |
| Forward P/E | N/A | 54.01 |
| P/S ratio | 39.05 | 4.10 |
| P/B ratio | 2.34 | 5.29 |
| EV / EBITDA | N/A | 26.55 |
| FCF yield | N/A | 2.89% |
Profitability
| Metric | RXRX | TMDX |
|---|---|---|
| Gross margin | -61.96% | 58.69% |
| Operating margin | -867.87% | 12.21% |
| Net margin | -945.92% | 22.69% |
| ROE | -56.71% | 29.28% |
| ROIC | -49.78% | 5.87% |
Growth (annualized)
| Metric | RXRX | TMDX |
|---|---|---|
| Revenue CAGR (5Y) | 45.50% | 86.12% |
| Total return CAGR (5Y) | -28.56% | 19.20% |
Frequently asked
- Which has grown faster, RXRX or TMDX?
- Over the past five years, TMDX grew revenue faster — RXRX at a 45.50% CAGR versus TMDX at 86.12%.
- Is RXRX or TMDX more profitable?
- TMDX runs the higher net margin — RXRX at -945.92% versus TMDX at 22.69%.
- How have RXRX and TMDX total returns compared?
- Over the past 5 years, RXRX delivered -28.56% and TMDX delivered 19.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
TransMedics P/E ratioRecursion Pharmaceuticals ROETransMedics ROERecursion Pharmaceuticals operating marginTransMedics operating marginRecursion Pharmaceuticals revenue growthTransMedics revenue growthRecursion Pharmaceuticals free cash flowTransMedics free cash flow
Recursion Pharmaceuticals & TransMedics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.